N-(2,3-二氢-1H-茚-1-基)硫二酰胺 | 15211-60-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: N-(2,3-二氢-1H-茚-1-基)硫二酰胺
• 英文名称: 1-(sulfamoylamino)-2,3-dihydro-1H-indene
• CAS: 15211-60-6
• 化学式: C₉H₁₂N₂O₂S
• 分子量: 212.272
• InChiKey: XDMSKLUZMCCHNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-氨基茚满 在 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 N-(2,3-二氢-1H-茚-1-基)硫二酰胺
  参考文献：
  名称：

  Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors

  摘要：

  Sulfamides represent an important class of biologically active compounds. A series of novel sulfamides were synthesized from 1-aminoindanes, 1-aminotetralin, 2-aminoindanes and 2-aminotetralin via the reactions of free amines, benzyl alcohol and chlorosulfonyl isocyanate (CSI) followed by hydrogenolysis of the obtained sulfamoylcarbamates. Carbonic anhydrase (CA, EC 4.2.1.1) inhibitory effects of the new sulfamides have been investigated. The human (h) isozymes hCA I and hCA II have been investigated in this study by using an esterase assay with 4-nitrophenyl acetate as substrate. The new sulfamides showed inhibition constants in the micro-submicromolar range, with one compound (N-(indane-1-yl) sulfamide) showing a K-i of 0.45 mu M against hCA I and of 1.07 mu M against hCA II. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.019

文献信息

• NOVEL INDANESULFAMlDE DERIVATIVES
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20140371319A1

  公开（公告）日：2014-12-18

  Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.

  新型印丹磺胺衍生物或其药用盐，如N-[(1S)-2,2,5,7-四氟-2,3-二氢-1H-茚基]磺胺，N-[(1S)-2,2,4,7-四氟-2,3-二氢-1H-茚基]磺胺，(+)-N-(2,2,4,6,7-五氟-2,3-二氢-1H-茚基)磺胺，在小鼠电击模型中具有改善癫痫严重程度指数（得分）的作用。因此，这些化合物或其药用盐有望作为治疗癫痫的药物。
• Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1884515A1

  公开（公告）日：2008-02-06

  The present invention refers to new indanyl sulphonamide compounds with general formula (I), as well as to their preparation procedure, their application as medicine and the pharmaceuticals composition which they are made up of. The new compounds of formula I show affinity for 5-HT6 receptors and are, therefore, effective for treating diseases mediated by these receptors.

  本发明涉及通式（I）的新茚基磺酰胺化合物，以及它们的制备方法、作为药物的应用和由它们组成的药物组合物。 式 I 的新化合物显示出对 5-HT6 受体的亲和力，因此可有效治疗由这些受体介导的疾病。
• NOVEL INDANESULFAMIDE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2865663A1

  公开（公告）日：2015-04-29

  Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.

  新型茚磺酰胺衍生物或其药学上可接受的盐，如 N-[(1S)-2,2,5,7-四氟-2,3-二氢-1H-茚-1-基]硫酰胺、N-[(1S)-2,2,4,7-四氟-2、N-[(1S)-2,2,4,7-四氟-2,3-二氢-1H-茚-1-基]硫酰胺、(+)-N-(2,2,4,6,7-五氟-2,3-二氢-1H-茚-1-基)硫酰胺具有改善小鼠电击模型癫痫发作严重程度指数（Score）的作用。因此，这些化合物或其盐有望成为治疗癫痫的药物。
• THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP3085369A1

  公开（公告）日：2016-10-26

  A medicine comprising a 1-indansulfamides compound such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, or N-[(1S)-2,2-triffuoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sulfamide or a pharmaceutically acceptable salt thereof, has an analgesic effects in the mouse hot-plate test and rat constriction nerve injury model and thus holds promise as a therapeutic agent for acute and chronic pain.

  一种包含 1-茚磺酰胺化合物（如 N-[(1S)-2,2,5,7-四氟-2,3-二氢-1H-茚-1-基]硫酰胺或 N-[(1S)-2,2-三氟-7-甲基-2,3-二氢-1H-茚-1-基]硫酰胺或其药学上可接受的盐类）的药物、在小鼠热板试验和大鼠收缩神经损伤模型中具有镇痛效果，因此有望作为急性和慢性疼痛的治疗剂。
• EPILEPSY TREATMENT AGENT
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP3769759A1

  公开（公告）日：2021-01-27

  Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b']dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.

  提供了一种将 N-[(1S)-2,2,5,7-四氟-2,3-二氢-1H-茚-1-基]硫酰胺与 AMPA 型谷氨酸受体拮抗剂（如 3-(2-氰基苯基)-5-(2-吡啶基)-1-苯基-1、2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b']二吡啶-9-基）苯甲腈，它具有作为癫痫治疗剂的潜力。